Showing 1421-1430 of 1564 results for "".
- The Vision Council Concludes Virtual Annual Business Meetinghttps://modernod.com/news/the-vision-council-concludes-virtual-annual-business-meeting/2480592/The Vision Council hosted its annual Business Meeting in a virtual format January 24. Presented under the banner of “It’s All Connected,” the meeting included a welcome address from Karen Roberts, The Vision Council’s Chair, followed by remarks from Ashley Mil
- Novartis Acquires Gyroscope Therapeutics, Maker of Investigational Gene Therapy for Geographic Atrophyhttps://modernod.com/news/novartis-acquires-gyroscope-therapeutics-maker-of-investigational-gene-therapy-for-geographic-atrophy/2480532/Novartis has bolstered it gene therapy portfolio after entering into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics. Novartis will make an upfront payment of $800 million and potential additi
- I-MED Pharma USA Gains Exclusive Distribution Rights for ESW Vision’s E>Eye and Tearcheck in the United Stateshttps://modernod.com/news/i-med-pharma-usa-gains-exclusive-distribution-rights-for-esw-visions-eeye-and-tearcheck-in-the-united-states/2480505/I-MED Pharma has announced the expansion of their strategic partnership with ESW Vision in France to be their exclusive distributor in the United States. Through I-MED Pharma USA, two dry eye devices will be available directly to all eye care professionals across the country. E>Eye i
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-2-vivid-study-of-brimochol-for-the-treatment-of-presbyopia/2480481/Visus Therapeutics reported positive topline results from VIVID, the company’s phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia. All three investigational candidates studied in VIVID achieved the endpoint of 3 lines of improvem
- Inspecs Acquires Hardy Amies Brandhttps://modernod.com/news/inspecs-acquires-hardy-amies-brand/2480476/Inspecs, a designer, manufacturer and distributor of eyewear frames and lenses, has announced the acquisition of the Hardy Amies brand, including all global intellectual property rights. Terms of the deal were not disclosed. Hardy Amies was founded by Sir Hardy Amie
- Patricia Bath, MD, Inducted Into National Inventors Hall of Famehttps://modernod.com/news/patricia-bath-md-inducted-into-national-inventors-hall-of-fame/2480295/Patricia Bath, MD, was among seven innovation pioneers inducted into the National Inventors Hall of Fame (NIHF) Dr. Bath, who was inducted posthumously, contributed to the invention of laserphaco, allowing surgeons to use ultrasound to perform all steps of cataract r
- AMA: Look to Ophthalmology for a Glimpse of Telemedicine’s Futurehttps://modernod.com/news/ama-look-to-ophthalmology-for-a-glimpse-of-telemedicines-future/2479477/Early on in the COVID-19 pandemic, ophthalmology struggled to adapt to telemedicine. It just wasn’t set up for virtual visits. “Ophthalmology is an exam-heavy specialty, and we really rely on all the clinical clues that we capture—either at the slit lamp, or looking at the retina, or check
- Glaucoma Devices’ Expanding Role to Drive Double-Digit Market Growthhttps://modernod.com/news/glaucoma-devices-expanding-role-to-drive-double-digit-market-growth/2479465/Glaucoma surgical devices will see increased use in all stages of disease and in stand-alone glaucoma procedures over the next 5 years, as companies commercialize more devices designed to meet these needs, according to a Market Scope report. Market Scope expects the glaucoma surgical devi
- Allegro Announces Positive Results of Vehicle-Controlled Ex-US Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/allegro-announces-positive-results-of-vehicle-controlled-ex-us-phase-2-trial-of-alg-1007-for-the-treatment-of-dry-eye-disease/2479410/Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-US vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, MD, at the 2021 American Society of Cataract and Refractive S
- Tarsus Announces Positive Results of Saturn-1 Trial Evaluating TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-announces-positive-results-of-saturn-1-trial-evaluating-tp-03-for-the-treatment-of-demodex-blepharitis/2479309/Tarsus Pharmaceuticals announced that all pre-specified primary and secondary endpoints were met for its pivotal Phase 2b/3 Saturn-1 trial evaluating the company’s novel investigational therapeutic, TP-03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis. Results demons